AR108277A2 - Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas - Google Patents

Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas

Info

Publication number
AR108277A2
AR108277A2 ARP170101125A ARP170101125A AR108277A2 AR 108277 A2 AR108277 A2 AR 108277A2 AR P170101125 A ARP170101125 A AR P170101125A AR P170101125 A ARP170101125 A AR P170101125A AR 108277 A2 AR108277 A2 AR 108277A2
Authority
AR
Argentina
Prior art keywords
seq
hiv fusion
biological properties
improved biological
inhibiting peptides
Prior art date
Application number
ARP170101125A
Other languages
English (en)
Original Assignee
Trimeris Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trimeris Inc filed Critical Trimeris Inc
Publication of AR108277A2 publication Critical patent/AR108277A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se provee un péptido inhibidor de fusión de HIV con una secuencia de aminoácidos de cualquiera de SEQ ID Nº 9, SEQ ID Nº 10, SEQ ID Nº 11, SEQ ID Nº 12, SEQ ID Nº 13, SEQ ID Nº 14, o SEQ ID Nº 15; y se provee una composición farmacéutica que comprende un péptido inhibidor de fusión de HIV y uno o más de un portador farmacéuticamente aceptable y portador macromolecular, y los usos y métodos de tratamiento provisto por estas composiciones.
ARP170101125A 2006-02-02 2017-05-02 Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas AR108277A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76467406P 2006-02-02 2006-02-02

Publications (1)

Publication Number Publication Date
AR108277A2 true AR108277A2 (es) 2018-08-01

Family

ID=38437849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070100450A AR059300A1 (es) 2006-02-02 2007-02-02 Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
ARP170101125A AR108277A2 (es) 2006-02-02 2017-05-02 Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070100450A AR059300A1 (es) 2006-02-02 2007-02-02 Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas

Country Status (15)

Country Link
US (3) US7456251B2 (es)
EP (1) EP1989220B1 (es)
JP (1) JP4682251B2 (es)
CN (1) CN101415723B (es)
AR (2) AR059300A1 (es)
AT (1) ATE537183T1 (es)
AU (1) AU2007218025A1 (es)
CA (1) CA2651793C (es)
CY (1) CY1113115T1 (es)
DK (1) DK1989220T3 (es)
ES (1) ES2381631T3 (es)
NZ (1) NZ570300A (es)
PT (1) PT1989220E (es)
TW (1) TWI341844B (es)
WO (1) WO2007097903A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties
CN101874038A (zh) * 2007-09-25 2010-10-27 特里梅里斯公司 治疗性抗-hiv肽的合成方法
EP2291392B1 (en) * 2008-05-28 2014-03-05 New York Blood Center Bifunctional molecules for inhibiting hiv entry
AU2009281992A1 (en) * 2008-08-13 2010-02-18 New York Blood Center Combination therapy of HIV fusion/entry inhibitors targeting gp41
WO2010045613A1 (en) * 2008-10-16 2010-04-22 New York Blood Center Immunoenhancer-linked oligomeric hiv vaccines
WO2010047826A2 (en) * 2008-10-24 2010-04-29 Trimeris, Inc. Dosing regimens and dosage formulations of an antiviral peptide therapeutic
CN102307588A (zh) * 2009-02-09 2012-01-04 纽约血库公司 用于治疗或预防hiv感染的三聚体hiv融合抑制剂
US8828932B2 (en) 2010-05-03 2014-09-09 New York Blood Center, Inc. Bifunctional molecules for inactivating HIV and blocking HIV entry
JP2015502378A (ja) * 2011-12-19 2015-01-22 ヤンセン・アールアンドデイ・アイルランド Ｈｉｖ膜融合阻害剤
US20150045291A1 (en) 2012-04-04 2015-02-12 Yeda Research And Development Co., Ltd. Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CN103724404B (zh) * 2013-12-08 2016-11-02 北京工业大学 抑制hiv病毒与宿主细胞融合的非对映体多肽及其用途
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN109320593A (zh) * 2018-11-05 2019-02-12 中国人民解放军军事科学院军事医学研究院 抑制hiv感染的螺旋多肽及其用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
JPS55154991A (en) 1979-05-23 1980-12-02 Hisamitsu Pharmaceut Co Inc Beta-d-fructopyranoside derivative
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4629783A (en) 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US5234520A (en) 1987-03-20 1993-08-10 Morgan Adhesives Co. Method of making an adhesive construction
CN1030256A (zh) * 1987-06-29 1989-01-11 日清食品株式会社 检测和治疗人类免疫缺陷病毒的方法和物质
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5462863A (en) 1989-02-09 1995-10-31 Development Center For Biotechnology Isolation of Hepatitis B surface antigen from transformed yeast cells
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
WO1993007603A1 (en) 1991-10-04 1993-04-15 Cornett Robert H Approaching emergency vehicle warning system
KR100358209B1 (ko) 1992-07-20 2003-01-24 듀크 유니버시티 Hiv복제를저해하는조성물
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
AU685784B2 (en) 1993-02-23 1998-01-29 Genentech Inc. Excipient stabilization of polypeptides treated with organic solvents
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6479055B1 (en) 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
AU723537B2 (en) 1995-06-07 2000-08-31 Trimeris Inc. The treatment of HIV and other viral infections using combinatorial therapy
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
US6919372B1 (en) 1997-12-26 2005-07-19 Yamanouchi Pharmaceutical Co., Ltd. Sustained release pharmaceutical compositions
JPH11209456A (ja) * 1998-01-29 1999-08-03 Hitachi Chem Co Ltd 印刷配線板用難燃性エポキシ樹脂組成物及びこれを用いたプリプレグ、金属箔張り積層板
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
EP1179012B2 (en) 1999-05-17 2009-07-15 ConjuChem Biotechnologies Inc. Long lasting fusion peptide inhibitors of viral infection
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
JP4460892B2 (ja) 2001-06-21 2010-05-12 ジェネンテック インコーポレイテッド 徐放性組成物
CN1100564C (zh) 2001-08-29 2003-02-05 周根发 用于治疗hiv感染的药物、其组合物及其用途
US7045552B2 (en) 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
AU2004313242A1 (en) 2004-01-07 2005-07-28 Trimeris, Inc. HIV gp41 HR2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus
CA2556032A1 (en) * 2004-03-15 2005-09-29 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides
KR101276422B1 (ko) 2004-03-15 2013-06-19 넥타르 테라퓨틱스 Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트
TWI341844B (en) 2006-02-02 2011-05-11 Trimeris Inc Hiv fusion inhibitor peptides with improved biological properties

Also Published As

Publication number Publication date
JP4682251B2 (ja) 2011-05-11
EP1989220A2 (en) 2008-11-12
US8034899B2 (en) 2011-10-11
US20090105143A1 (en) 2009-04-23
CA2651793C (en) 2015-07-07
WO2007097903A2 (en) 2007-08-30
PT1989220E (pt) 2012-03-23
TW200806687A (en) 2008-02-01
CY1113115T1 (el) 2016-04-13
CN101415723A (zh) 2009-04-22
EP1989220B1 (en) 2011-12-14
US7456251B2 (en) 2008-11-25
NZ570300A (en) 2011-08-26
JP2009525051A (ja) 2009-07-09
ATE537183T1 (de) 2011-12-15
TWI341844B (en) 2011-05-11
EP1989220A4 (en) 2009-05-06
CA2651793A1 (en) 2007-08-30
AR059300A1 (es) 2008-03-26
DK1989220T3 (da) 2012-04-02
US20120040891A1 (en) 2012-02-16
AU2007218025A1 (en) 2007-08-30
CN101415723B (zh) 2014-06-25
US20070179278A1 (en) 2007-08-02
WO2007097903A3 (en) 2008-05-22
ES2381631T3 (es) 2012-05-30

Similar Documents

Publication Publication Date Title
AR108277A2 (es) Péptidos inhibidores de fusión de hiv con propiedades biológicas mejoradas
ES2721172T3 (es) Una nueva clase de moléculas terapéuticas a base de proteínas
UY28250A1 (es) Composiciones farmacéuticas para inhibidores de la proteasa del virus de la hepatitis c
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
NO20084008L (no) HLA-A 3303-begrenset WT1-peptid og farmasoytisk preparat omfattende det samme
ECSP10010413A (es) Inhibidores macrociclicos de serina proteasa
EP2270042A3 (en) KDR peptides and vaccines comprising the same
UY27650A1 (es) Composiciones farmacéuticas para inhibidores de proteasa viral de la hepatitis c
PE20161325A1 (es) L-asparaginasa tratada con peg
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
AU2003299519A1 (en) Hepatitis c virus inhibitors
MX2009012609A (es) Composiciones y metodos para producir proteinas de fusion bioactivas.
WO2007008657A3 (en) Hepatitis c virus inhibitors
WO2010034105A8 (en) Hepatitis c inhibitor compounds
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
RU2013126581A (ru) Мутанты стрептокиназы и их ковалентно модифицированные формы
AR030278A1 (es) Peptido modulador del receptor de trombopoyetina
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
HK1124075A (en) Hiv fusion inhibitor peptides with improved biological properties
AR057858A1 (es) Una composicion inhibidora de la agregacion plaquetaria
CO5780137A1 (es) Antigenos protectores y vacunas para el control de infestaciones por multiespecies de garrapatas
AR115255A2 (es) Péptidos biológicamente activos
DE10394174D2 (de) Peptide mit hohem Cysteingehalt

Legal Events

Date Code Title Description
FB Suspension of granting procedure